PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update

Publisher Name:
Published Date: 31-Jan-2014
No. of pages: 465

The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. In the emerging markets in particular, uptake of branded drugs will increase due to rapid economic growth. We anticipate that the type 2 diabetes market will not experience a fundamental shift in the classes of drugs that are preferred by physicians. Rapid uptake of drugs from the novel class of SGLT-2 inhibitors will occur; however, DPP-4 inhibitors and GLP-1 receptor agonists will continue dominating the noninsulin type 2 diabetes space. GLP-1 receptor agonists will experience the fastest growth of all classes (CAGR of 17%), due to their weight-loss effects and their novel once-weekly administration, which is preferable to the standard onceor twice-daily therapies.

Highlights

Key Questions Answered

  • Although the T2D market has numerous well-established therapies, it is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the T2D market?
  • The late-stage T2D pipeline is heavily populated with me-too drugs from the classes of GLP-1 receptor agonists, DPP-4 inhibitors and SGLT-2 inhibitors. Only one drug in Phase III development is first-inclass but resembles the me-too drugs in many aspects. Will the latestage drugs make a significant impact on the T2D market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
  • The diagnosed prevalence of T2D in the world skyrocketed in the past 10 years and will continue increasing at the fast pace. How will epidemiological changes impact the growth of the future market?

Key Findings

  • The main driver of the enormous expansion of the T2D market will be the dramatic increase in disease prevalence, which is attributable to increased life expectancy and an increasingly sedentary and stressful lifestyle.
  • The second largest driver will be the physicians’ efforts to delay disease progression through the use of combination therapies and novel branded drugs.
  • With the recent therapeutic guidelines putting emphasis on a patient-tailored approach in treating type 2 diabetes, pharmaceutical companies will achieve considerable success with their me-too drugs.
  • In the future, companies will have to shift their focus towards competitive pricing and towards “niche” drugs aimed at smaller patient groups.
  • To date, no drug has demonstrated sustainable efficacy in the treatment of T2D. This unmet need presents a large opportunity for investment by drug developers.

Scope

  • Overview of T2D, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized T2D therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the T2D therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global T2D therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global T2D therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global T2D therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global T2D therapeutics market from 2012-2022.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents For This Report

Table of Contents

1 Table of Contents 11

1.1 List of Tables 19

1.2 List of Figures 27

2 Introduction 29

2.1 Catalyst 29

2.2 Related Reports 30

3 Disease Overview 31

3.1 Etiology and Pathophysiology 31

3.1.1 Etiology 31

3.1.2 Pathophysiology 32

3.1.3 Prognosis 33

3.1.4 Quality of Life 34

3.2 Symptoms 34

4 Epidemiology 36

4.1 Risk Factors and Comorbidities 36

4.1.1 Family history of diabetes is a strong predictor of type 2 diabetes 37

4.1.2 The risk of type 2 diabetes increases dramatically around age 50 38

4.1.3 The risk of developing type 2 diabetes increases as BMI increases 39

4.1.4 Gestational diabetes increases the risk of developing type 2 diabetes later in life up to 10 times 40

4.1.5 Up to 75% of adults with type 2 diabetes have hypertension 41

4.1.6 Nearly all type 2 diabetics also have dyslipidemia 42

4.2 Global Trends 43

4.2.1 US 43

4.2.2 5EU 47

4.2.3 Japan 50

4.2.4 Brazil 52

4.2.5 China and India 52

4.3 Forecast Methodology 54

4.3.1 Sources Used 57

4.3.2 Forecast Assumptions and Methods 67

4.3.3 Sources Not Used 76

4.4 Epidemiology Forecast of Type 2 Diabetes (2012-2022) 77

4.4.1 Prevalent Cases of Diagnosed Type 2 Diabetes 77

4.4.2 Age-Specific Prevalent Cases of Diagnosed Type 2 Diabetes 79

4.4.3 Sex-Specific Prevalent Cases of Diagnosed Type 2 Diabetes 81

4.4.4 Age-Standardized Prevalence of Diagnosed Type 2 Diabetes 83

4.4.5 Overweight/Obesity among Diagnosed Prevalent Cases of Type 2 Diabetes 84

4.4.6 Hypertension among Diagnosed Prevalent Cases of Type 2 Diabetes 86

4.4.7 Dyslipidemia among Diagnosed Prevalent Cases of Type 2 Diabetes 88

4.5 Discussion 89

4.5.1 Limitations of the Analysis 92

4.5.2 Strengths of the Analysis 93

5 Disease Management 95

5.1 Treatment Overview 95

5.1.1 Diagnosis and Referrals 95

5.1.2 Treatment Guidelines 96

5.2 US 102

5.2.1 Diagnosis 102

5.2.2 Clinical Practice 102

5.3 France 103

5.3.1 Diagnosis 103

5.3.2 Clinical Practice 103

5.4 Germany 104

5.4.1 Diagnosis 104

5.4.2 Clinical Practice 104

5.5 Italy 106

5.5.1 Diagnosis 106

5.5.2 Clinical Practice 107

5.6 Spain 109

5.6.1 Diagnosis 109

5.6.2 Clinical Practice 109

5.7 UK 110

5.7.1 Diagnosis 110

5.7.2 Clinical Practice 112

5.8 Japan 114

5.8.1 Diagnosis 114

5.8.2 Clinical Practice 114

5.9 China 115

5.9.1 Diagnosis 115

5.9.2 Clinical Practice 116

5.10 India 117

5.10.1 Diagnosis 117

5.10.2 Clinical Practice 117

5.11 Brazil 118

5.11.1 Diagnosis 118

5.11.2 Clinical Practice 118

6 Competitive Assessment 119

6.1 Overview 119

6.2 Strategic Competitor Assessment 120

6.3 Product Profiles – Major Brands 122

6.3.1 Metformin 122

6.3.2 Sulfonylureas (SUs) and Other Insulin Secretagogues 127

6.3.3 ?-glucosidase Inhibitors (AGIs) 133

6.3.4 Thiazolidinediones (TZDs) 137

6.3.5 GLP-1 Receptor Agonists 142

6.3.6 DPP-4 Inhibitors 165

6.3.7 SGLT-2 Inhibitors 194

6.3.8 Insulin Formulations 204

7 Opportunity and Unmet Need 231

7.1 Overview 231

7.2 Unmet Needs 232

7.2.1 Drugs Providing Sustained Glycemic Control 232

7.2.2 Drugs with Non-Glycemic Benefits 233

7.2.3 Increased Patient Compliance 234

7.2.4 Drugs with Improved Side-Effect Profiles 235

7.2.5 Earlier Diagnosis 236

7.3 Unmet Needs Gap Analysis 237

7.4 Oral Therapy with Sustainable Efficacy 238

7.5 Oral Therapy Offering Weight Loss 238

7.6 Cardio-metabolic Therapy 239

7.7 Promotion of Type 2 Diabetes Drugs in Emerging Markets 239

8 Pipeline Assessment 240

8.1 Overview 240

8.2 Clinical Trial Mapping 241

8.2.1 Clinical Trials by Country 241

8.3 Clinical Trials by Phase and Trial Status 242

8.4 Promising Drugs in Clinical Development 244

8.4.1 Albiglutide 248

8.4.2 Dulaglutide (LY2189265) 254

8.4.3 Semaglutide 261

8.4.4 Trelagliptin (SYR-472) 266

8.4.5 MK-3102 270

8.4.6 Empagliflozin 275

8.4.7 Tofogliflozin 281

8.4.8 Ipragliflozin 286

8.4.9 LY2409021 291

8.4.10 LY2605541 (insulin peglispro) 296

9 Current and Future Players 302

9.1 Overview 302

9.2 Trends in Corporate Strategy 305

9.3 Company Profiles 306

9.3.1 Eli Lilly 306

9.3.2 Bristol-Myers Squibb 309

9.3.3 Novo Nordisk 313

9.3.4 Sanofi 316

9.3.5 GlaxoSmithKline 318

9.3.6 AstraZeneca 320

9.3.7 Merck & Co 322

9.3.8 Boehringer Ingelheim 324

9.3.9 Takeda 326

9.3.10 Roche 329

9.3.11 Pfizer 330

9.3.12 Johnson & Johnson 332

10 Market Outlook 334

10.1 Global Markets 334

10.1.1 Forecast 334

10.1.2 Drivers and Barriers – Global Issues 339

10.2 US 340

10.2.1 Forecast 340

10.2.2 Key Events 345

10.2.3 Drivers and Barriers 346

10.3 France 348

10.3.1 Forecast 348

10.3.2 Key Events 352

10.3.3 Drivers and Barriers 353

10.4 Germany 355

10.4.1 Forecast 355

10.4.2 Key Events 359

10.4.3 Drivers and Barriers 360

10.5 Italy 361

10.5.1 Forecast 361

10.5.2 Key Events 365

10.5.3 Drivers and Barriers 366

10.6 Spain 367

10.6.1 Forecast 367

10.6.2 Key Events 371

10.6.3 Drivers and Barriers 372

10.7 UK 374

10.7.1 Forecast 374

10.7.2 Key Events 378

10.7.3 Drivers and Barriers 379

10.8 Japan 381

10.8.1 Forecast 381

10.8.2 Key Events 385

10.8.3 Drivers and Barriers 386

10.9 China 388

10.9.1 Forecast 388

10.9.2 Key Events 392

10.9.3 Drivers and Barriers 393

10.10 India 395

10.10.1 Forecast 395

10.10.2 Key Events 399

10.10.3 Drivers and Barriers 399

10.11 Brazil 402

10.11.1 Forecast 402

10.11.2 Key Events 406

10.11.3 Drivers and Barriers 406

11 Appendix 410

11.1 Bibliography 410

11.2 Abbreviations 442

11.3 Methodology 445

11.4 Forecasting Methodology 445

11.4.1 Diagnosed Type 2 Patients 446

11.4.2 Percent Drug-Treated Patients 446

11.4.3 Drugs Included in Each Therapeutic Class 446

11.4.4 Launch and Patent Expiry Dates 447

11.4.5 General Pricing Assumptions 448

11.4.6 Individual Drug Assumptions 449

11.4.7 Generic Erosion 458

11.4.8 Pricing of Pipeline Agents 458

11.5 Physicians and Specialists Included in this Study 460

11.6 About the Authors 462

11.6.1 Analyst II – CVMD 462

11.6.2 Therapy Director – CVMD and Infectious Disease 462

11.6.3 Senior Epidemiologist 463

11.6.4 Global Head of Healthcare 463

11.7 About GlobalData 464

11.8 Disclaimer 464

List of Tables

Table 1: Symptoms of Type 2 Diabetes 35

Table 2: Risk Factors and Comorbidities of Type 2 Diabetes 37

Table 3: Prevalence (%) of Diabetes in Japan, 1964-1992 51

Table 4: Prevalence (%) of Diabetes in Japan, by Sex, 1997-2007 51

Table 5: Prevalence (%) of Diabetes in Japan, by Age, 2007 51

Table 6: Epidemiological Sources for Type 2 Diabetes Prevalence in the 10 Major Markets 55

Table 7: 10 Major Markets, Epidemiological Sources of Comorbidities: Overweight and Obesity 56

Table 8: Select Major Markets, Epidemiological Sources of Comorbidities: Hypertension 56

Table 9: Select Major Markets, Epidemiological Sources of Comorbidities: Dyslipidemia 57

Table 10: All Markets, Prevalent Cases of Type 2 Diabetes, Ages ?20 Years, Both Sexes, N (Millions), 2012-2022 78

Table 11: All Markets, Prevalent Cases of Type 2 Diabetes by Age, N (Millions), (Row %), 2012 80

Table 12: All Markets, Prevalent Cases of Diagnosed Type 2 Diabetes by Sex, Ages ?20 Years, N (Millions) (Row %), 2012 82

Table 13: All Markets, Prevalent Cases of Overweight/Obesity among Type 2 Diabetics, Both Sexes, Ages ?20 Years, N (Millions), 2012 85

Table 14: All Markets, Prevalent Cases of Hypertension among Diagnosed Type 2 Diabetics, Both Sexes, Ages ?20 Years, N (Millions), 2012 86

Table 15: All Markets, Prevalent Cases of Dyslipidemia among Diagnosed Type 2 Diabetics, Both Sexes, Ages ?20 Years, N (Millions), 2012 88

Table 16: Diagnostic Tests and Typical Criteria for Type 2 Diabetes 95

Table 17: Treatment Guidelines for Type 2 Diabetes 97

Table 18: Most-Prescribed Drugs (Following Metformin and Sulfonylureas) for Type 2 Diabetes by Class in the Global Markets, 2012 100

Table 19: Leading Branded Treatments for Type 2 Diabetes, 2012 121

Table 20: Product Profile – Metformin 124

Table 21: Metformin SWOT Analysis, 2012 126

Table 22: Global Sales Forecasts ($m) for Metformin, 2012-2022 127

Table 23: First-Generation Sulfonylureas 129

Table 24: Second-Generation Sulfonylureas 129

Table 25: Product Profile – Sulfonylureas 130

Table 26: Sulfonylureas SWOT Analysis, 2012 131

Table 27: Global Sales Forecasts ($m) for SUs, 2012-2022 132

Table 28: Product Profile – Acarbose 134

Table 29: AGIs SWOT Analysis, 2012 136

Table 30: Global Sales Forecasts ($m) for AGIs, 2012-2022 137

Table 31: Product Profile – Actos 139

Table 32: Actos SWOT Analysis, 2012 141

Table 33: Global Sales Forecasts ($m) for Actos, 2012-2022 142

Table 34: GLP-1 Receptor Agonists 144

Table 35: Product Profile – Byetta 146

Table 36: Byetta SWOT Analysis, 2012 148

Table 37: Global Sales Forecasts ($m) for Byetta, 2012-2022 149

Table 38: Product Profile – Victoza 151

Table 39: Victoza SWOT Analysis, 2012 153

Table 40: Global Sales Forecasts ($m) for Victoza, 2012-2022 154

Table 41: Product Profile – Bydureon 156

Table 42: Bydureon SWOT Analysis, 2012 158

Table 43: Global Sales Forecasts ($m) for Bydureon, 2012-2022 159

Table 44: Product Profile – Lyxumia 161

Table 45: Lyxumia SWOT Analysis, 2012 164

Table 46: Global Sales Forecasts ($m) for Lyxumia, 2012-2022 165

Table 47: Marketed DPP-4 Inhibitors 167

Table 48: Marketed DPP-4 Inhibitors in Combination with Other OADs 167

Table 49: Product Profile – Januvia 169

Table 50: Januvia SWOT Analysis, 2012 171

Table 51: Global Sales Forecasts ($m) for Januvia and Janumet, 2012-2022 172

Table 52: Product Profile – Onglyza 174

Table 53: Onglyza SWOT Analysis, 2012 176

Table 54: Global Sales Forecasts ($m) for Onglyza and Kombiglyze, 2012-2022 178

Table 55: Product Profile – Tradjenta 179

Table 56: Tradjenta SWOT Analysis, 2012 182

Table 57: Product Profile – Galvus 185

Table 58: Galvus SWOT Analysis, 2012 188

Table 59: Global Sales Forecasts ($m) for Galvus and Eucreas, 2012-2022 189

Table 60: Product Profile – Nesina 191

Table 61: Nesina SWOT Analysis, 2012 193

Table 62: Global Sales Forecasts ($m) for Nesina and Oseni and Kazano, 2012-2022 194

Table 63: Product Profile – Forxiga 196

Table 64: Forxiga SWOT Analysis, 2012 198

Table 65: Global Sales Forecasts ($m) for Forxiga, 2012-2022 199

Table 66: Product Profile – Invokana 201

Table 67: Invokana SWOT Analysis, 2012 203

Table 68: Global Sales Forecasts ($) for Invokana, 2012-2022 204

Table 69: Insulins – Overview and Comparison 205

Table 70: Insulin Formulations 206

Table 71: Product Profile – Humalog 207

Table 72: Humalog SWOT Analysis, 2012 209

Table 73: Global Sales Forecasts ($m) for Humalog, 2012-2022 210

Table 74: Product Profile – Lantus 211

Table 75: Lantus SWOT Analysis, 2012 214

Table 76: Global Sales Forecasts ($m) for Lantus Franchise, 2012-2022 215

Table 77: Product Profile – Levemir 216

Table 78: Levemir SWOT Analysis, 2012 218

Table 79: Global Sales Forecasts ($m) for Levemir, 2012-2022 219

Table 80: Product Profile – Novolog 220

Table 81: Novolog SWOT Analysis, 2012 221

Table 82: Global Sales Forecasts ($m) for Novolog, 2012-2022 222

Table 83: Product Profile – Apidra 223

Table 84: Apidra SWOT Analysis, 2012 225

Table 85: Global Sales Forecasts ($m) for Apidra, 2012-2022 226

Table 86: Product Profile – Tresiba 227

Table 87: Tresiba SWOT Analysis, 2012 229

Table 88: Global Sales Forecasts ($) for Tresiba, 2012-2022 230

Table 89: Overall Unmet Needs – Current Level of Attainment 231

Table 90: Clinical Unmet Needs – Gap Analysis, 2013 237

Table 91: Type 2 Diabetes – Clinical Trials by Phase and Status, 2012 243

Table 92: Type 2 Diabetes – Phase Pipeline, 2012 246

Table 93: Comparison of Therapeutic Classes in Development for Type 2 Diabetes, 2012 247

Table 94: Product Profile – Albiglutide 249

Table 95: Albiglutide SWOT Analysis, 2013 253

Table 96: Global Sales Forecasts ($m) for Albiglutide, 2012-2022 254

Table 97: Product Profile – Dulaglutide 255

Table 98: Dulaglutide SWOT Analysis, 2012 259

Table 99: Global Sales Forecasts ($m) for Dulaglutide, 2012-2022 260

Table 100: Product Profile – Semaglutide 262

Table 101: Semaglutide SWOT Analysis, 2012 264

Table 102: Global Sales Forecasts ($m) for Semaglutide, 2012-2022 265

Table 103: Product Profile – Trelagliptin 267

Table 104: Trelagliptin SWOT Analysis, 2013 269

Table 105: Global Sales Forecasts ($m) for Trelagliptin, 2012-2022 270

Table 106: Product Profile – MK-3102 271

Table 107: MK-3102 SWOT Analysis, 2013 273

Table 108: Global Sales Forecasts ($m) for MK-3102, 2012-2022 274

Table 109: Product Profile – Empagliflozin 276

Table 110: Empagliflozin SWOT Analysis, 2013 279

Table 111: Global Sales Forecasts ($m) for Empagliflozin, 2012-2022 280

Table 112: Product Profile – Tofogliflozin 282

Table 113: Tofogliflozin SWOT Analysis, 2013 284

Table 114: Global Sales Forecasts ($m) for tofogliflozin, 2012-2022 285

Table 115: Product Profile – Ipragliflozin 287

Table 116: Ipragliflozin SWOT Analysis, 2013 289

Table 117: Global Sales Forecasts ($m) for Ipragliflozin, 2012-2022 290

Table 118: Product Profile – LY2409021 292

Table 119: LY2409021 SWOT Analysis, 2013 294

Table 120: Global Sales Forecasts ($m) for LY2409021, 2012-2022 295

Table 121: Product Profile – LY2605541 297

Table 122: LY2605541 SWOT Analysis, 2013 300

Table 123: Global Sales Forecasts ($) for LY2605541, 2012-2022 301

Table 124: Key Companies in the Type 2 Diabetes Market, 2012 303

Table 125: Other Companies in the Type 2 Diabetes Market, 2012 304

Table 126: Eli Lilly’s Type 2 Diabetes Portfolio Assessment, 2013 308

Table 127: Eli Lilly SWOT Analysis, 2012 309

Table 128: Bristol-Myers Squibb’s Type 2 Diabetes Portfolio Assessment, 2013 311

Table 129: Bristol-Myers Squibb SWOT Analysis, 2012 312

Table 130: Novo Nordisk’s Type 2 Diabetes Portfolio Assessment, 2013 314

Table 131: Novo Nordisk SWOT Analysis, 2012 315

Table 132: Sanofi’s Type 2 Diabetes Portfolio Assessment, 2013 317

Table 133: Sanofi SWOT Analysis, 2012 318

Table 134: GSK’s Type 2 Diabetes Portfolio Assessment, 2013 319

Table 135: GSK SWOT Analysis, 2012 320

Table 136: AstraZeneca’s Type 2 Diabetes Portfolio Assessment, 2013 321

Table 137: AstraZeneca SWOT Analysis, 2012 322

Table 138: Merck’s Type 2 Diabetes Portfolio Assessment, 2013 323

Table 139: Merck SWOT Analysis, 2012 324

Table 140: Boehringer Ingelheim’s Type 2 Diabetes Portfolio Assessment, 2013 325

Table 141: Boehringer Ingelheim SWOT Analysis, 2012 326

Table 142: Takeda’s Type 2 Diabetes Portfolio Assessment, 2013 328

Table 143: Takeda SWOT Analysis, 2012 328

Table 144: Roche’s Type 2 Diabetes Portfolio Assessment, 2013 329

Table 145: Roche SWOT Analysis, 2012 330

Table 146: Pfizer’s Type 2 Diabetes Portfolio Assessment, 2013 331

Table 147: Pfizer SWOT Analysis, 2012 331

Table 148: J&J’s Type 2 Diabetes Portfolio Assessment, 2013 332

Table 149: J&J SWOT Analysis, 2012 333

Table 150: Global Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 336

Table 151: Type 2 Diabetes Market – Drivers and Barriers, 2012 339

Table 152: US Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 342

Table 153: Key Events Impacting Sales for Type 2 Diabetes in the US, 2012-2022 345

Table 154: Type 2 Diabetes Market – Drivers and Barriers in the US, 2012 346

Table 155: France Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 349

Table 156: Key Events Impacting Sales for Type 2 Diabetes in France, 2012-2022 352

Table 157: Type 2 Diabetes Market – Drivers and Barriers in France, 2012 353

Table 158: Germany Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 356

Table 159: Key Events Impacting Sales for Type 2 Diabetes in Germany, 2012-2022 359

Table 160: Type 2 Diabetes Market – Drivers and Barriers in Germany, 2012 360

Table 161: Italy Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 362

Table 162: Key Events Impacting Sales for Type 2 Diabetes in Italy, 2012-2022 365

Table 163: Type 2 Diabetes Market – Drivers and Barriers in Italy, 2012 366

Table 164: Spain Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 368

Table 165: Key Events Impacting Sales for Type 2 Diabetes in Spain, 2012-2022 371

Table 166: Type 2 Diabetes Market – Drivers and Barriers in Spain, 2012 372

Table 167: UK Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 375

Table 168: Key Events Impacting Sales for Type 2 Diabetes in the UK, 2012-2022 378

Table 169: Type 2 Diabetes Market – Drivers and Barriers in the UK, 2012 379

Table 170: Japan Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 382

Table 171: Key Events Impacting Sales for Type 2 Diabetes in Japan, 2012-2022 385

Table 172: Type 2 Diabetes Market – Drivers and Barriers in Japan, 2012 386

Table 173: China Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 389

Table 174: Key Events Impacting Sales for Type 2 Diabetes in China, 2012-2022 392

Table 175: Type 2 Diabetes Market – Drivers and Barriers in China, 2012 393

Table 176: India Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 396

Table 177: Key Events Impacting Sales for Type 2 Diabetes in India, 2012-2022 399

Table 178: Type 2 Diabetes Market – Drivers and Barriers in India, 2012 399

Table 179: Brazil Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 403

Table 180: Key Events Impacting Sales for Type 2 Diabetes in Brazil, 2012-2022 406

Table 181: Type 2 Diabetes Market – Drivers and Barriers in Brazil, 2012 406

Table 182: Key Launch Dates 447

Table 183: Key Patent Expiries 447

Table 184: Number of High-Prescribing Physicians Surveyed 461

List of Figures

Figure 1: Crude and Age-Adjusted Incidence (per 1,000 population) of Diagnosed Diabetes in the US, Ages 18-79 Years, 1980-2011 44

Figure 2: Crude and Age-Adjusted Prevalence (%) of Diagnosed Diabetes in the US, Ages ?18 Years, 1980-2010 45

Figure 3: Age-Specific Prevalence of Diagnosed Diabetes in the US, 1980-2011 46

Figure 4: Age-Adjusted Prevalence of Diagnosed Diabetes in the US, by Sex, Ages ?18 Years, 1980-2011 46

Figure 5: Age-Adjusted Prevalence (%) of Diagnosed Diabetes, France, Germany and Italy, 1999-2007 48

Figure 6: Age-Adjusted Prevalence (%) of Diagnosed Type 2 Diabetes in Spain, 1987-2006, by Sex, 1987-2006 49

Figure 7: Age-Adjusted Prevalence (%) of Diagnosed Diabetes in the UK, 1996-2011 49

Figure 8: Age-Adjusted Prevalence (%) of Diagnosed Diabetes, UK, 1994-1998, by Sex 50

Figure 9: Urban-Rural Differences in the Age-Adjusted Prevalence (%) of Diabetes in China and India, 1992-2008 53

Figure 10: All Markets, Prevalent Cases of Type 2 Diabetes, Ages ?20 Years, N (Millions), 2012-2022 78

Figure 11: All Markets, Prevalent Cases of Diagnosed Type 2 Diabetes, by Age, N (Millions), 2012 81

Figure 12: All Markets, Prevalent Cases of Diagnosed Type 2 Diabetes by Sex, Ages ?20 Years, N (Millions), 2012 82

Figure 13: All Markets, Age-Standardized Prevalence of Diagnosed Type 2 Diabetes, Ages ?20 Years, Men and Women, %, 2012 84

Figure 14: All Markets, Prevalent Cases of Overweight/Obesity among Diagnosed Type 2 Diabetes, Both Sexes, Ages ?20 Years, N (Millions), 2012 85

Figure 15: All Markets, Prevalent Cases of Hypertension among Diagnosed Type 2 Diabetes, Both Sexes, Ages ?20 Years, N (Millions), 2012 87

Figure 16: All Markets, Prevalent Cases of Dyslipidemia among Diagnosed Type 2 Diabetics, Both Sexes, Ages ?20 Years, N (Millions), 2012 89

Figure 17: ADA/EASD General Recommendations for Antihyperglycemic Therapy 99

Figure 18: Type 2 Diabetes Therapeutics – Clinical Trials by Country, 2012 242

Figure 19: Competitive Assessment of Late-Stage Pipeline Agents in Type 2 Diabetes, 2012-2022 247

Figure 20: Company Portfolio Gap Analysis in Type 2 Diabetes, 2012-2022 304

Figure 21: Global Sales for Type 2 Diabetes by Region, 2011-2022 338

Figure 22: Sales for Type 2 Diabetes in the US by Drug Class, 2012-2022 344

Figure 23: Sales for Type 2 Diabetes in France by Drug Class, 2012-2022 351

Figure 24: Sales for Type 2 Diabetes in Germany by Drug Class, 2012-2022 358

Figure 25: Sales for Type 2 Diabetes in Italy by Drug Class, 2012-2022 364

Figure 26: Sales for Type 2 Diabetes in Spain by Drug Class, 2012-2022 370

Figure 27: Sales for Type 2 Diabetes in the UK by Drug Class, 2012-2022 377

Figure 28: Sales for Type 2 Diabetes in Japan by Drug Class, 2012-2022 384

Figure 29: Sales for Type 2 Diabetes in China by Drug Class, 2012-2022 391

Figure 30: Sales for Type 2 Diabetes in India by Drug Class, 2012-2022 398

Figure 31: Sales for Type 2 Diabetes in Brazil by Drug Class, 2012-2022 405

Get Updates

Share This Post

Latest Reports from Life Sciences category

© 2014 MarketOptimizer.org. All rights reserved.